Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment

Betsy Goodfellow | April 15, 2024 | News story | Research and Development Columbi, Genentech, Oncology, Roche, clinical trial, lymphoma 

Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has met its primary endpoint of overall survival. The trial assessed Columvi (glofitamab-gxbm) for the treatment of patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), who have had at least one prior therapy and are not candidates for autologous stem cell transplant.

The drug is a ‘CD20xCD3 T-cell engaging bispecific antibody designed to be off-the-shelf and ready for infusion, so patients can start treatment soon after diagnosis’, according to the company’s press release.

Columvi in combination with gemcitabine and oxaliplatin (GemOx) was shown to improve patients’ overall survival when compared to Rituxan (rituximab) in combination with GemOx. The combination appeared to be similar to the known safety profiles of the two individual drugs.

The full data is expected to be shared at an upcoming medical meeting as well as being submitted to the relevant health authorities.

Levi Garraway MD PhD, Genentech’s chief medical officer and head of global product development, commented: “People with this aggressive lymphoma facing relapse or progression after initial treatment have limited options – particularly those who are ineligible for stem cell transplant. Building on Columvi’s established benefits, these data demonstrate the potential of this combination regimen to improve survival outcomes in earlier lines of treatment.”

Betsy Goodfellow

Related Content

diana-polekhina-zbsthwt9vlc-unsplash_2

AstraZeneca shares results from phase 3 trial of COVID-19 prevention drug

AstraZeneca has announced positive high-level results from the SUPERNOVA phase 3 trial for a COVID-19 …

FDA approves Roche’s HPV self-collection screening option

Roche has announced that the US Food and Drug Administration (FDA) has approved its human …

AstraZeneca shares positive interim results from phase 3 lymphoma trial

AstraZeneca has announced positive high-level results from an interim analysis of the ECHO phase 3 …

Latest content